Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.

ABSTRACT:

Background

Secondary hyperparathyroidism (sHPT), a complication of chronic kidney disease (CKD) characterized by persistently elevated parathyroid hormone (PTH), alterations in calcium-phosphorus homeostasis, and vitamin D metabolism, affects 50% of children receiving dialysis. A significant proportion of these children develop CKD-mineral and bone disorder (CKD-MBD), associated with an increased risk of fractures and vascular calcification. The standard of care for sHPT in children includes vitamin D sterols, calcium supplementation, and phosphate binders. Several agents are approved for sHPT treatment in adults undergoing dialysis, including vitamin D analogs and calcimimetics, with limited information on their safety and efficacy in children. The calcimimetic cinacalcet is appro

SUBMITTER: Warady BA 

PROVIDER: S-EPMC7385021 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature